Increased platelet content of SDF-1alpha is associated with worse prognosis in patients with pulmonary prterial hypertension. (19th May 2019)

• Record Type: Journal Article
• Authors: Kazimierczyk, Remigiusz; Blaszczak, Piotr; Jasiewicz, Małgorzata; Knapp, Małgorzata; Ptaszynska-Kopczynska, Katarzyna; Sobkowicz, Bozena; Waszkiewicz, Ewa; Grzywna, Ryszard; Musial, Wlodzimierz J.; Kaminski, Karol A.
• Is Part Of: Platelets. Volume 30:Number 4(2019)
• Page Start: 445
• Page End: 451
• Publication Date: 2019-05-19
• Subjects: Interleukin 6 -- interleukin 6 receptor -- platelets -- pulmonary arterial hypertension -- SDF-1; Blood platelets -- Periodicals; Blood Platelets -- Periodicals; 615.39
• DOI: 10.1080/09537104.2018.1457780
• Languages: English
• ISSNs: 0953-7104

Abstract

Abstract: Inflammatory processes and platelet activity play an important role in the pathophysiology of pulmonary arterial hypertension (PAH). Enhanced IL-6 signaling and higher concentration of stromal-derived factor alpha (SDF-1) have been previously shown to be linked with prognosis in PAH. We hypothesized that platelets of PAH patients have higher content of IL-6 and SDF-1 and thus are involved in disease progression. We enrolled into study 22 PAH patients and 18 healthy controls. Patients with PAH presented significantly higher plasma concentrations and platelet contents of IL-6, sIL-6R, and SDF-1 than healthy subjects (platelet content normalized to protein concentration: IL-6 (0.85*10 –10 [0.29 – 1.37] vs. 0.45*10 –10 [0.19–0.65], sIL-6R 1.54*10 –7 [1.32–2.21] vs. 1.14*10 –7 [1.01–1.28] and SDF-1 (2.72*10 –7 [1.85–3.23] vs. 1.70*10 –7 [1.43–2.60], all p < 0.05). Patients with disease progression (death, WHO class worsening, or therapy escalation, n = 10) had a significantly higher platelet SDF-1/total platelet protein ratio (3.68*10 –7 [2.45–4.62] vs. 1.69*10 –7 [1.04–2.28], p = 0.001), with no significant differences between plasma levels. Kaplan–Meier analysis revealed that patients with higher platelet SDF-1/total platelet protein ratio had more frequently deterioration of PAH in the follow-up (15.24 ± 4.26 months, log-rank test, p = 0.01). Concentrations of IL-6, sIL-6 receptor and SDF-1 in plasma and platelets are elevated in PAH patients. Higher content of SDF-1 in platelets is associated with poorer prognosis. Our study, despite of limitation due to small number of enrolled patients, suggests that activated platelets may be an important source of cytokines at the site of endothelial injury, but their exact role in the pathogenesis of PAH requires further investigation.